Danisco sells part of Genencor's Health Care product portfolio
As announced on 1 August 2005, Genencor continued the development activities for GCR-8015 (pre-clinical) and GCR-3888 (clinical), two compounds for hematological malignancies. These activities have been successfully divested to CAT, which will also be hiring certain former Genencor key employees to be responsible for the development of these programmes.
CAT may be required to pay Danisco an additional consideration of up to USD 2 million, contingent on the availability for use in a clinical trial of bulk product material produced by Genencor, bringing the total consideration up to a possible USD 16 million.
From 1 November 2005, there will no longer be any staff employed in Genencor's Health Care segment.
The net restructuring costs involved and the possible proceeds from the sale of the Health Care activities were included in Danisco's previously announced DKK 300-350 million range of special items for 2005/06.
Most read news
Organizations
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.